ArticleMolecular biology reports2025
Evaluation of antibiotic resistance in emerging strains of Bacillus cereus and antibiotic potency estimations of Oxytetracycline.
Article in Molecular biology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAntimicrobial resistance (AMR) is the greatest threat to the global clinical and healthcare sectors due to the emergence of mutagenic and multidrug-resistant (MDR) strains in the environmental contaminants. Thus, it is essential to regularly monitor these novel microbial strains for its genomic variations and antibiotic susceptibility assessments. The quality of the antibiotic produced is also a concern for national and international drug approval regulatory bodies, which assess the antibiotic potency of medications. In this study, we are estimating simultaneously the antibiotic sensitivity of emerging Bacillus cereus isolates as well as potency of manufactured antibiotics against these emerging indigenous strains. The standard test drug used for analysis is Oxytetracycline along with reference strain Bacillus cereus (ATCC 11778) for determining the antibiotic potency of test drug against new strains of B. cereus. METHODS AND
resultsBacterial identification will be performed using series of biochemical tests followed by 16 s rRNA gene sequencing. According to the pharmacological test procedures of antibiotic assay, their antimicrobial sensitivity against oxytetracycline was estimated using the Cup-plate antibiotic assay. Simultaneously, the test antibiotics potency was calculated using two-level factorial antibiotic assay method of to determine the drug's effectiveness against two test strains of B. cereus. The observed ZOI at high and low dilutions (16 µg/ml-4 µg/ml) of the Oxytetracycline (IPRS reference standard origin) was found to be (30.2-25.0 mm) for ATCC 11778, (29.0-25 mm) for AIR-01 and (17 mm-13 mm) for EW-01, respectively. The calculated potency of for Bacillus cereus (ATCC 11778) was 95.32%, whereas the potency for the indigenous B. cereus AIR-01 was 86.84% due to its low sensitivity towards oxytetracycline.
conclusionsThe calculated antibiotic potency of oxytetracycline against Bacillus cereus (ATCC 11778) was reported to be 95.32%, while the antibiotic potency against native B. cereus (AIR-01) was found to be 86.84%, which cannot be calculated for (EW-01) due to the presence of a moderate to complete antimicrobial resistance against the test drug sample.
Indexed as
Identifiers
41065949What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.